Advertisement

Journal of Genetic Counseling

, Volume 24, Issue 5, pp 744–751 | Cite as

Personalized Medicine Through SNP Testing for Breast Cancer Risk: Clinical Implementation

  • Rebecca Howe
  • Talya Miron-Shatz
  • Yaniv Hanoch
  • Zehra B. Omer
  • Cristina O’Donoghue
  • Elissa M. OzanneEmail author
Original Research

Abstract

Single nucleotide polymorphisms (SNPs) have the potential to improve personalized medicine in breast cancer care. As new SNPs are discovered, further enhancing risk classification, SNP testing may serve to complement family history and phenotypic risk factors when assessed in a clinical setting. SNP analysis is particularly relevant to high-risk women who may seek out such information to guide their decision-making around risk-reduction. However, little is known about how high-risk women may respond to SNP testing with regard to clinical decision-making. We examined high-risk women’s interest in SNP testing for breast cancer risk through an online survey of hypothetical testing scenarios. Women stated their preferences for sharing test results and selected the most likely follow-up action they would pursue in each of the test result scenarios (above average and below average risk for breast cancer). Four hundred seventy-eight women participated. Most women (89 %) did not know what a SNP was prior to the study. Once SNP testing was described, 75 % were interested in SNP testing. Participants stated an interest in lifestyle interventions for risk-reduction and wanted to discuss their testing results with their doctor or a genetic counselor. Women are interested in SNP testing and are prepared to make lifestyle changes based on testing results. Women’s preference for discussing testing results with a healthcare provider aligns with the current trend towards SNP testing in a clinical setting.

Keywords

Breast cancer Risk assessment SNP testing Decision making 

Notes

Acknowledgments

This work was supported in part by grant number MRSG112037 from the American Cancer Society. Additional resources for this study were obtained from the Cancer Genetics Network (RFA CA-97-004, RFA CA-97-019, RFP No. N01-PC-55049-40), a University of Plymouth award, and a European Research Council Marie Curie Reintegration Grant [No. PIRG7-GA-2010-268224]. These funding sources ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report. We would also like to thank Elaine Allen for her guidance with the statistical analysis for this study.

Human Studies and Informed Consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.

Conflicts of Interest

Rebecca Howe, Talya Miron-Shatz, Yaniv Hanoch, Zehra B. Omer, Cristina O’Donoghue, and Elissa M. Ozanne declare that they have no conflict of interest.

References

  1. Annas, G. J., & Elias, S. (2014). 23andMe and the FDA. The New England Journal of Medicine, 370(11), 985–988.PubMedGoogle Scholar
  2. Antoniou, A. C., Beesley, J., McGuffog, L., Sinilnikova, O. M., Healey, S., Neuhausen, S. L., & Easton, D. F. (2010). Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Research, 70(23), 9742–9754.PubMedPubMedCentralGoogle Scholar
  3. Bellcross, C. A., Page, P. Z., & Meaney-Delman, D. (2012). Direct-to-consumer personal genome testing and cancer risk prediction. Cancer Journal (Sudbury, Mass.), 18(4), 293–302. Retrieved from https://doi.org/www.ncbi.nlm.nih.gov/pubmed/22846729.Google Scholar
  4. Bloss, C. S., Schork, N. J., & Topol, E. J. (2011). Effect of direct-to-consumer genomewide profiling to assess disease risk. The New England Journal of Medicine, 364(6), 524–534.PubMedPubMedCentralGoogle Scholar
  5. Bowen, D., Hickman, K. M., & Powers, D. (1997). Importance of psychological variables in understanding risk perceptions and breast cancer screening of African American women. Women’s Health (Hillsdale, N.J.), 3(3–4), 227–242. Retrieved from https://doi.org/www.ncbi.nlm.nih.gov/pubmed/9426495.Google Scholar
  6. Brentnall, A. R., Evans, D. G., & Cuzick, J. (2014). Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK. British Journal of Cancer, 110(3), 827–828.PubMedPubMedCentralGoogle Scholar
  7. Campa, D., Kaaks, R., Le Marchand, L., Haiman, C. A., Travis, R. C., Berg, C. D., & Canzian, F. (2011). Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. Journal of the National Cancer Institute, 103(16), 1252–1263.PubMedPubMedCentralGoogle Scholar
  8. Cyrus-David, M. S. (2010). Knowledge and accuracy of perceived personal risk in underserved women who are at increased risk of breast cancer. Journal of Cancer Education : The Official Journal of the American Association for Cancer Education, 25(4), 617–623.Google Scholar
  9. Daly, M. B., Lerman, C. L., Ross, E., Schwartz, M. D., Sands, C. B., & Masny, A. (1996). Gail model breast cancer risk components are poor predictors of risk perception and screening behavior. Breast Cancer Research and Treatment, 41(1), 59–70.PubMedGoogle Scholar
  10. Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D. P., Thompson, D., Ballinger, D. G., & Ponder, B. A. J. (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447(7148), 1087–1093.PubMedPubMedCentralGoogle Scholar
  11. Edwards, A. G., Naik, G., Ahmed, H., Elwyn, G. J., Pickles, T., Hood, K., & Playle, R. (2013). Personalised risk communication for informed decision making about taking screening tests. Cochrane Database of Systematic Reviews (Online), 2, CD001865.Google Scholar
  12. Fagerlin, A., Zikmund-Fisher, B. J., Ubel, P. A., Jankovic, A., Derry, H. A., & Smith, D. M. (2007). Measuring numeracy without a math test: development of the Subjective Numeracy Scale. Medical Decision Making : An International Journal of the Society for Medical Decision Making, 27(5), 672–680. doi: https://doi.org/10.1177/0272989X07304449.Google Scholar
  13. Frosch, D. L., May, S. G., Rendle, K. A. S., Tietbohl, C., & Elwyn, G. (2012). Authoritarian physicians and patients’ fear of being labeled “difficult” among key obstacles to shared decision making. Health Affairs (Project Hope), 31(5), 1030–1038. doi: https://doi.org/10.1377/hlthaff.2011.0576.Google Scholar
  14. Graves, K. D., Peshkin, B. N., Luta, G., Tuong, W., & Schwartz, M. D. (2011). Interest in genetic testing for modest changes in breast cancer risk: implications for SNP testing. Public Health Genomics, 14(3), 178–189.PubMedPubMedCentralGoogle Scholar
  15. Gray, S. W., O’Grady, C., Karp, L., Smith, D., Schwartz, J. S., Hornik, R. C., & Armstrong, K. (2009). Risk information exposure and direct-to-consumer genetic testing for BRCA mutations among women with a personal or family history of breast or ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 18(4), 1303–1311.Google Scholar
  16. Gurmankin, A., Domchek, S., Stopfer, J., Fels, C., & Armstrong, K. (2005). Patients’ resistance to risk information in genetic counseling for BRCA1/2. Archives of Internal Medicine, 14(165), 523–529. Retrieved from https://doi.org/vpn.ucsf.edu/pubmed/,DanaInfo=www.ncbi.nlm.nih.gov+?term=gurmankin+2005+patients’+resistance+to+risk.Google Scholar
  17. Hall, T. O., Renz, A. D., Snapinn, K. W., Bowen, D. J., & Edwards, K. L. (2012). Awareness and uptake of direct-to-consumer genetic testing among cancer cases, their relatives, and controls: the Northwest Cancer Genetics Network. Genetic Testing and Molecular Biomarkers, 16(7), 744–748.PubMedPubMedCentralGoogle Scholar
  18. Heald, B., Edelman, E., & Eng, C. (2012). Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers. European Journal of Human Genetics : EJHG, 20(5), 547–551.PubMedGoogle Scholar
  19. Hock, K. T., Christensen, K. D., Yashar, B. M., Roberts, J. S., Gollust, S. E., & Uhlmann, W. R. (2011). Direct-to-consumer genetic testing: an assessment of genetic counselors’ knowledge and beliefs. Genetics in Medicine : Official Journal of the American College of Medical Genetics, 13(4), 325–332. doi: https://doi.org/10.1097/GIM.0b013e3182011636.Google Scholar
  20. Ingham, S. L., Warwick, J., Byers, H., Lalloo, F., Newman, W. G., & Evans, D. G. R. (2012). Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK. Clinical Genetics. Retrieved from https://doi.org/www.ncbi.nlm.nih.gov/pubmed/23050611
  21. Ingle, J. N., Liu, M., Wickerham, D. L., Schaid, D. J., Wang, L., Mushiroda, T., & Weinshilboum, R. M. (2013). Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. Cancer Discovery, 3(7), 812–825.PubMedPubMedCentralGoogle Scholar
  22. Kaphingst, K. A., McBride, C. M., Wade, C., Alford, S. H., Reid, R., Larson, E., … Brody, L. C. (2012). Patients’ understanding of and responses to multiplex genetic susceptibility test results. Genetics in Medicine : Official Journal of the American College of Medical Genetics. Retrieved from https://doi.org/www.ncbi.nlm.nih.gov/pubmed/22481132
  23. Kaufman, D. J., Bollinger, J. M., Dvoskin, R. L., & Scott, J. A. (2012). Risky business: risk perception and the use of medical services among customers of DTC personal genetic testing. Journal of Genetic Counseling, 21(3), 413–422.PubMedGoogle Scholar
  24. Mealiffe, M. E., Stokowski, R. P., Rhees, B. K., Prentice, R. L., Pettinger, M., & Hinds, D. A. (2010). Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. Journal of the National Cancer Institute, 102(21), 1618–1627.PubMedPubMedCentralGoogle Scholar
  25. Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M., Dennis, J., Milne, R. L., & Easton, D. F. (2013). Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 45(4), 353–361. doi: https://doi.org/10.1038/ng.2563.PubMedPubMedCentralGoogle Scholar
  26. Offit, K. (2011). Personalized medicine: new genomics, old lessons. Human Genetics, 130(1), 3–14. doi: https://doi.org/10.1007/s00439-011-1028-3.PubMedPubMedCentralGoogle Scholar
  27. Powell, K. P., Cogswell, W. A., Christianson, C. A., Dave, G., Verma, A., Eubanks, S., & Henrich, V. C. (2012). Primary care physicians’ awareness, experience and opinions of direct-to-consumer genetic testing. Journal of Genetic Counseling, 21(1), 113–126. doi: https://doi.org/10.1007/s10897-011-9390-9.PubMedGoogle Scholar
  28. Riordan, S., Rodriguez, D. F., & Kieran, S. (2012). Personal genomic testing as part of the complete breast cancer risk assessment: a case report. Journal of Genetic Counseling, 21(5), 638–644.PubMedGoogle Scholar
  29. Schwartz, L. M., Woloshin, S., Black, W. C., & Welch, H. G. (1997). The role of numeracy in understanding the benefit of screening mammography. Annals of Internal Medicine, 127(11), 966–972.PubMedGoogle Scholar
  30. Senay, I., & Kaphingst, K. A. (2009). Anchoring-and-adjustment bias in communication of disease risk. Medical Decision Making : An International Journal of the Society for Medical Decision Making, 29(2), 193–201.Google Scholar
  31. van’t Veer, L. J., & Bernards, R. (2008). Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature, 452(7187), 564–570. doi: https://doi.org/10.1038/nature06915.Google Scholar
  32. Vernon, S. W. (1999). Risk perception and risk communication for cancer screening behaviors: a review. Journal of the National Cancer Institute Monographs, 25, 101–119. Retrieved from https://doi.org/www.ncbi.nlm.nih.gov/pubmed/10854465.Google Scholar
  33. Weitzel, J. N., Blazer, K. R., & Macdonald, D. J. (2011). Genetics, Genomics, and Cancer Risk Assessment State of the Art and Future Directions in the Era of Personalized Medicine. CA: Cancer Journal for Clinicians, 61(5), 327–359. doi: https://doi.org/10.3322/caac.20128.Available.Google Scholar

Copyright information

© National Society of Genetic Counselors, Inc. 2014

Authors and Affiliations

  • Rebecca Howe
    • 1
  • Talya Miron-Shatz
    • 2
  • Yaniv Hanoch
    • 3
  • Zehra B. Omer
    • 4
  • Cristina O’Donoghue
    • 5
    • 6
  • Elissa M. Ozanne
    • 6
    • 7
    Email author
  1. 1.Frank H. Netter MD School of MedicineQuinnipiac UniversityNorth HavenUSA
  2. 2.Center for Medical Decision MakingOno Academic CollegeKiryat OnoIsrael
  3. 3.Department of PsychologyPlymouth UniversityPlymouthUK
  4. 4.School of MedicineUniversity of MassachusettsWorcesterUSA
  5. 5.Department of SurgeryUniversity of Illinois at ChicagoChicagoUSA
  6. 6.Department of SurgeryUniversity of California at San FranciscoSan FranciscoUSA
  7. 7.The Dartmouth Institute for Health Policy and Clinical PracticeLebanonUSA

Personalised recommendations